Efficacy of venlafaxine in geriatric depression

Depression and Anxiety

Volumn 12, Issue SUPPL. 1, 2000, Pages 63-68

  Staab, Jeffrey P ^a,b   Evans, Dwight L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antidepressive agent; Clinical trials; Comorbidity; Elderly; Geriatric psychiatry; Human; Major depression; Norepinephrine; Review; Serotonin

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DOSULEPIN; FLUOXETINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AGED; AGITATION; ANXIETY NEUROSIS; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DOSE KIDNEY FUNCTION RELATION; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INSOMNIA; META ANALYSIS; NAUSEA; NEUROPATHY; PAIN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; STROKE; TREATMENT OUTCOME; XEROSTOMIA;

AGED; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; HUMANS; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0033767674     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/1520-6394(2000)12:1+<63::AID-DA8>3.0.CO;2-T     Document Type: Review

References (52)

1. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: Intraindividual variability and plasma concentration correlations
2. Long-term treatment of geropsychiatric depressed patients with venlafaxine
3. Evidence-based guidelines for nearing depressive disorders with antidepressants: A revision of the 1993 British Association for Psychopharmacology guidelines
4. Psychopharmacologic treatment of depression in the medically ill
5. Mood disorders
6. Depressive disorders in the medically ill: An overview
7. Therapy of early poststroke depression with venlafaxine: Safety, tolerability, and efficacy as determined in an open, uncontrolled clinical trial
8. Painful peripheral diabetic neuropathy treated with venlafaxine HCl extended release capsules
9. New options in pharmacotherapy for geriatric depression: Limiting side effects and drug interactions
10. Pharmacokinetic considerations of antidepressant use in the elderly
11. An open-label evaluation of the long-term safety of oral venlafaxine in depressed elderly patients
12. An open clinical trial of venlafaxine treatment of fibromyalgia
13. Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system
14. Depression in the medical setting: Biopsychological interactions and treatment considerations
15. Depression in the medically ill: Management considerations
16. Cardiovascular safety in depressed patients: Focus on venlafaxine
17. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: Effect of metabolic inhibitors and SSRI antidepressants
18. Depression following myocardial infarction. Impact on 6-month survival
19. Depression and 18-month prognosis after myocardial infarction
20. Antidepressant use in the elderly. Current stares of nefazodone, venlafaxine, and meclobemide
21. Evidence of the dual mechanism of action of venlafaxine
22. Venlafaxine in depressed geriatric outpatients: An open-label clinical study
23. Depression and chronic medical illness
24. Effects of age and gender on venlafaxine and O-desmethyl-venlafaxine pharmacokinetics
25. A randomized, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depression
26. An assessment of the efficacy of venlafaxine extended-release in elderly patients with generalized anxiety disorder
27. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder
28. The relationship of depression to cardiovascular disease: Epidemiology, biology, and treatment
29. Antidepressant chemical profile of the novel bicyclic compound WY 45, 030, an ethyl cyclohexanol derivative
30. Prophylaxis of migraine: Open study with venlafaxine in 42 patients
31. Newer antidepressants and the cytochrome P450 system
32. Diagnosis and treatment of depression
33. New antidepressants and the cytochrome P450 system: Focus on venlafaxine, nefazodone, and mirtazepine
34. Are the newer antidepressant drugs as effective as established physical treatments? Review from an Australasian clinical panel review
35. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomized comparison
36. Nortriptyline vs. fluoxetine in the treatment of depression and in short-term recovery after stroke: A placebo-controlled, double-blind study
37. The diagnosis and treatment of late-life depression
38. The safety, and tolerability of venlafaxine hydrochloride: Analysis of the clinical trials database
39. A meta-analysis of the effects of venlafaxine on anxiety associated with depression
40. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression
41. Practical considerations for the treatment of depression in elderly and very elderly long-term care patients
42. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder
43. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety
44. Double-blind, randomized study of venlafaxine, clomipramine and trazodone in geriatric patients with major depression
45. Cerebrovascular disease and depression symptoms in the cardiovascular health study
46. Major depression in medically ill patients
47. Effects of venlafaxine on blood pressure: A meta-analysis of original data from 3744 depressed patients
48. The effect of renal disease on the disposition of venlafaxine
49. Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms
50. Antidepressant efficacy and cardiovascular safety of venlafaxine in young vs. old patients with comorbid medical disorders